The question with reverse settlement or “pay-for-delay” deal is that whether the settlement terms are being used to postpone or weaken generic competition.
#PADP8670
#PADP8670
September 29, 2026 at 9:16 PM
The question with reverse settlement or “pay-for-delay” deal is that whether the settlement terms are being used to postpone or weaken generic competition.
#PADP8670
#PADP8670
Patent settlements can avoid costly litigation and preserve incentives for innovation. Yet private agreements may restrict competition and harm consumers. As firms shift toward non-cash arrangements, effective antitrust oversight becomes more challenging.
#PADP8670
#PADP8670
September 29, 2026 at 9:16 PM
Patent settlements can avoid costly litigation and preserve incentives for innovation. Yet private agreements may restrict competition and harm consumers. As firms shift toward non-cash arrangements, effective antitrust oversight becomes more challenging.
#PADP8670
#PADP8670
A lesser-known issue in pharma patent settlements is that a generic can be allowed to enter the market, but only if it agrees to limit how much it sells. The FTC identified 23 agreements involving 8 drugs with these “quantity restrictions.”
#PADP8670
#PADP8670
Reverse Payments: From Cash to Quantity Restrictions and Other Possibilities
Today, staff of the Bureau of Competition published four reports covering fiscal years 2018,
www.ftc.gov
September 29, 2026 at 6:02 PM
A lesser-known issue in pharma patent settlements is that a generic can be allowed to enter the market, but only if it agrees to limit how much it sells. The FTC identified 23 agreements involving 8 drugs with these “quantity restrictions.”
#PADP8670
#PADP8670
AI could make drug discovery faster, cheaper and less risky, weakening the case for long U.S. patent monopolies. If development costs fall, shorter exclusivity could still reward innovation while bringing generics and lower prices sooner. #PADP8670
September 29, 2026 at 10:37 PM
AI could make drug discovery faster, cheaper and less risky, weakening the case for long U.S. patent monopolies. If development costs fall, shorter exclusivity could still reward innovation while bringing generics and lower prices sooner. #PADP8670
everse settlements can benefit both brand-name and generic drug companies: the brand pays the generic firm to delay market entry, preserving profits while the generic receives compensation. But consumers may wait longer for cheaper drugs, raising antitrust concerns. #PADP8670
September 30, 2026 at 1:08 AM
everse settlements can benefit both brand-name and generic drug companies: the brand pays the generic firm to delay market entry, preserving profits while the generic receives compensation. But consumers may wait longer for cheaper drugs, raising antitrust concerns. #PADP8670
An FTC study found that patent settlements involving payments delayed generic entry by an average of 17 months compared with settlements without payments. This delay can keep lower-cost alternatives off the market and reduce competition. #PADP8670
www.ftc.gov/reports/pay-...
www.ftc.gov/reports/pay-...
www.ftc.gov
September 29, 2026 at 9:12 PM
An FTC study found that patent settlements involving payments delayed generic entry by an average of 17 months compared with settlements without payments. This delay can keep lower-cost alternatives off the market and reduce competition. #PADP8670
www.ftc.gov/reports/pay-...
www.ftc.gov/reports/pay-...
Cannabis legalization in the U.S tells a bigger story than marijuana itself. Since California opened the door to medical use in 1996, states have steadily rewritten the rules.
Today, cannabis policy seats at the crossroads of public health, criminal justice, tax revenue, and federalism.
#PADP8670
Today, cannabis policy seats at the crossroads of public health, criminal justice, tax revenue, and federalism.
#PADP8670
August 25, 2026 at 5:44 PM
Cannabis legalization in the U.S tells a bigger story than marijuana itself. Since California opened the door to medical use in 1996, states have steadily rewritten the rules.
Today, cannabis policy seats at the crossroads of public health, criminal justice, tax revenue, and federalism.
#PADP8670
Today, cannabis policy seats at the crossroads of public health, criminal justice, tax revenue, and federalism.
#PADP8670
Patent settlements can reduce litigation costs and uncertainty and may allow earlier generic entry. But when brands offer generics benefits to limit competition, firms may share monopoly rents at consumers’ expense. How can we distinguish beneficial settlements from anticompetitive ones? #PADP8670
September 29, 2026 at 2:25 PM
Patent settlements can reduce litigation costs and uncertainty and may allow earlier generic entry. But when brands offer generics benefits to limit competition, firms may share monopoly rents at consumers’ expense. How can we distinguish beneficial settlements from anticompetitive ones? #PADP8670
The Hatch-Waxman Act intended to encourage pharmaceutical innovation and generic competition. But the use of settlements to delay generic entry has consequences for consumers when lower-cost alternatives remain off market. How can policymakers balance patent protection and consumer access?#padp8670
September 29, 2026 at 2:14 PM
The Hatch-Waxman Act intended to encourage pharmaceutical innovation and generic competition. But the use of settlements to delay generic entry has consequences for consumers when lower-cost alternatives remain off market. How can policymakers balance patent protection and consumer access?#padp8670
Reverse settlements happen when brand-name drug companies pay generic makers to delay entering the market. An interesting fact I found that the patent holder pays the company accused of infringementthe opposite of a typical patent settlement. These deals can delay cheaper drugs.
#PADP8670
#PADP8670
September 29, 2026 at 7:53 PM
Reverse settlements happen when brand-name drug companies pay generic makers to delay entering the market. An interesting fact I found that the patent holder pays the company accused of infringementthe opposite of a typical patent settlement. These deals can delay cheaper drugs.
#PADP8670
#PADP8670
Reverse payment settlements ("pay-for-delay") occur when brand pharma pays generic challengers to delay market entry in Hatch-Waxman patent disputes. By splitting monopoly rents, firms avoid price competition at the expense of consumer welfare and public health budgets. #PADP8670
September 29, 2026 at 2:16 AM
Reverse payment settlements ("pay-for-delay") occur when brand pharma pays generic challengers to delay market entry in Hatch-Waxman patent disputes. By splitting monopoly rents, firms avoid price competition at the expense of consumer welfare and public health budgets. #PADP8670
...nature of pharmaceutical detailing, they also may be subconsciously (or consciously in some cases) influenced to prescribe drugs that they otherwise would not prescribe.
#PADP8670
#PADP8670
September 22, 2026 at 6:56 PM
...nature of pharmaceutical detailing, they also may be subconsciously (or consciously in some cases) influenced to prescribe drugs that they otherwise would not prescribe.
#PADP8670
#PADP8670
With new brand-name drugs, companies hold patent rights that generic manufacturers may challenge. Litigation may ensue and result in a "reverse settlement". These "pay-for-delay" settlements are investigated by the Federal Trade Commission, as they may reduce competition in the market.
#PADP8670
#PADP8670
September 29, 2026 at 6:56 PM
With new brand-name drugs, companies hold patent rights that generic manufacturers may challenge. Litigation may ensue and result in a "reverse settlement". These "pay-for-delay" settlements are investigated by the Federal Trade Commission, as they may reduce competition in the market.
#PADP8670
#PADP8670
U.S. law may give the first generic patent challenger 180 days of exclusivity. In a reverse payment settlement, a brand drugmaker gives the generic firm money or another benefit to delay entry. Large, unjustified deals may violate antitrust law. #PADP8670
September 28, 2026 at 8:36 PM
U.S. law may give the first generic patent challenger 180 days of exclusivity. In a reverse payment settlement, a brand drugmaker gives the generic firm money or another benefit to delay entry. Large, unjustified deals may violate antitrust law. #PADP8670
A 2010 FTC study estimated that pay-for-delay deals cost consumers and taxpayers about $3.5 billion a year in higher drug prices. Since the Medicare Modernization Act of 2003, drug companies have been required to file these settlements with the FTC and DOJ. #PADP8670
September 29, 2026 at 12:46 PM
A 2010 FTC study estimated that pay-for-delay deals cost consumers and taxpayers about $3.5 billion a year in higher drug prices. Since the Medicare Modernization Act of 2003, drug companies have been required to file these settlements with the FTC and DOJ. #PADP8670
The sneakiest form of pay-for-delay isn't cash. A brand drugmaker can promise not to launch its own cheap "authorized generic" during a rival generic's 180-day exclusivity, roughly doubling that rival's profits, in exchange for a later launch date. #PADP8670
September 29, 2026 at 3:24 AM
The sneakiest form of pay-for-delay isn't cash. A brand drugmaker can promise not to launch its own cheap "authorized generic" during a rival generic's 180-day exclusivity, roughly doubling that rival's profits, in exchange for a later launch date. #PADP8670
Reverse payment settlements: brand drugmakers pay generic rivals to delay entering the market instead of competing. FTC says this costs consumers ~$3.5B/yr in higher drug prices. SCOTUS ruled in FTC v. Actavis (2013) these deals aren't automatically legal — courts weigh them case-by-case. #PADP8670
September 30, 2026 at 2:22 AM
Reverse payment settlements: brand drugmakers pay generic rivals to delay entering the market instead of competing. FTC says this costs consumers ~$3.5B/yr in higher drug prices. SCOTUS ruled in FTC v. Actavis (2013) these deals aren't automatically legal — courts weigh them case-by-case. #PADP8670
Alternatively, the brand name drug manufacturer often chooses to counter the challenge by offering a "reverse-payment" settlement which provides the generic brand a piece of the "monopoly pie". It's a win-win for everyone (except the consumers). #PADP8670
How important are drug prices to you?
How important are drug prices to you?
September 29, 2026 at 6:31 PM
Alternatively, the brand name drug manufacturer often chooses to counter the challenge by offering a "reverse-payment" settlement which provides the generic brand a piece of the "monopoly pie". It's a win-win for everyone (except the consumers). #PADP8670
How important are drug prices to you?
How important are drug prices to you?
The issue of fuzzy entitlements can be applied to a contemporary issue: data center development. Local governments struggle with zoning for these new developments, developers capitalize on the lack of regulatory clarity, and local governments are slow to respond with updated codes. #PADP8670
September 28, 2026 at 8:42 PM
The issue of fuzzy entitlements can be applied to a contemporary issue: data center development. Local governments struggle with zoning for these new developments, developers capitalize on the lack of regulatory clarity, and local governments are slow to respond with updated codes. #PADP8670
Pharma/tech firms may boast 'innovation' but use patent-troll suits, pay-for-delay deals, and what Manganelli(2023) calls patent thickets-clusters of patents that make generic entry into a legal obstacle course. These strategies reinforce monopolies when they should reinforce 'innovation.' #PADP8670
September 29, 2026 at 3:08 AM
Pharma/tech firms may boast 'innovation' but use patent-troll suits, pay-for-delay deals, and what Manganelli(2023) calls patent thickets-clusters of patents that make generic entry into a legal obstacle course. These strategies reinforce monopolies when they should reinforce 'innovation.' #PADP8670
In 2010, the FTC produced a study highlighting the impact of "Pay for Delay" settlements and found that these agreements cost American consumers an estimated $3.5 billion dollars annually. Recent studies on this topic have proven that the actual cost is closer to $6.2 billion per year. #PADP8670
September 29, 2026 at 9:03 PM
In 2010, the FTC produced a study highlighting the impact of "Pay for Delay" settlements and found that these agreements cost American consumers an estimated $3.5 billion dollars annually. Recent studies on this topic have proven that the actual cost is closer to $6.2 billion per year. #PADP8670
Just learned about “reverse payment” settlements in the pharmaceutical industry today, where a brand-name drug company may pay a generic competitor as part of a patent settlement. What makes it tricky is whether it’s simply a settlement or actually “pay-for-delay” that reduces competition. #PADP8670
September 29, 2026 at 3:29 AM
Just learned about “reverse payment” settlements in the pharmaceutical industry today, where a brand-name drug company may pay a generic competitor as part of a patent settlement. What makes it tricky is whether it’s simply a settlement or actually “pay-for-delay” that reduces competition. #PADP8670
US marijuana policy reflects a its federalist government system: while federal law long rejected its medical use, many states legalized it. These policy differences help analysts study effects on health, prescribing, public spending, and behavior. #PADP8670
August 25, 2026 at 10:31 PM
US marijuana policy reflects a its federalist government system: while federal law long rejected its medical use, many states legalized it. These policy differences help analysts study effects on health, prescribing, public spending, and behavior. #PADP8670
Under the Hatch-Waxman Act, challenging a brand name drug may be profitable in more ways than one: either through market entry or a lucrative settlement.
If a generic drug company successfully wins the Paragraph IV challenge, then they are permitted to go to market with their drug [cont'd #PADP8670]
If a generic drug company successfully wins the Paragraph IV challenge, then they are permitted to go to market with their drug [cont'd #PADP8670]
September 29, 2026 at 6:29 PM
Under the Hatch-Waxman Act, challenging a brand name drug may be profitable in more ways than one: either through market entry or a lucrative settlement.
If a generic drug company successfully wins the Paragraph IV challenge, then they are permitted to go to market with their drug [cont'd #PADP8670]
If a generic drug company successfully wins the Paragraph IV challenge, then they are permitted to go to market with their drug [cont'd #PADP8670]
Pharmaceutical advertising to U.S. physicians creates incentives to prescribe more opioids, often less-safe substitutes to other perscriptions. Firms and doctors receive private benefits, while patients, families and taxpayers absorb addiction and overdose costs. #PADP8670
September 22, 2026 at 10:23 PM
Pharmaceutical advertising to U.S. physicians creates incentives to prescribe more opioids, often less-safe substitutes to other perscriptions. Firms and doctors receive private benefits, while patients, families and taxpayers absorb addiction and overdose costs. #PADP8670